Daratumumab, a human CD38 immunoglobulin G1 kappa (IgG1κ) monoclonal antibody, has
activity as monotherapy in multiple myeloma (MM). This phase 1/2 study investigated …

Background: In the phase 3 ALCYONE study, daratumumab plus bortezomib/melphalan/
prednisone (D-VMP) versus bortezomib/melphalan/prednisone (VMP) significantly improved …

Background Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (D-
RVd) in the GRIFFIN study improved the stringent complete response rate by the end of …

Abstract Background: Daratumumab (DARA)(HuMax™-CD38), a human IgG1κ monoclonal
antibody effectively mediates destruction of CD38-expressing malignant plasma cells. In the …

Methods Patients ineligible for high-dose chemotherapy with autologous stem cell
transplantation due to age≥ 65 years or comorbidities were randomized 1: 1 to Rd±DARA …

Introduction: Daratumumab (DARA) is a human anti-CD38 IgG1κ monoclonal antibody that
showed synergistic anti-tumor activity in combination with lenalidomide (LEN) in in vitro …

Introduction: DARA, a human IgGκ monoclonal antibody targeting CD38, is approved as
monotherapy and in combination with standard-of-care regimens for relapsed/refractory …

Background Lenalidomide plus dexamethasone is a standard treatment for patients with
newly diagnosed multiple myeloma who are ineligible for autologous stem-cell …

The phase 2 GRIFFIN study of daratumumab plus lenalidomide/bortezomib/dexamethasone
(D-RVd) for transplant-eligible, newly diagnosed multiple myeloma included a safety run-in …

Background Daratumumab showed encouraging efficacy as monotherapy in patients with
heavily pretreated multiple myeloma in the GEN501 and SIRIUS studies. Here we report a …